Market Place
Sourcing Support
Sellas Life Sciences Reports Q3 2024 Results & Corporate News
13 Nov 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences to Present at ASH 2024 Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Sellas Receives FDA Rare Pediatric Designation For Galinpepimut-S
15 Oct 2024 //
GLOBENEWSWIRE
Sellas Joins 2024 Maxim Healthcare Virtual Summit Fireside Chat
10 Oct 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
SELLAS Receives EMA Orphan Drug Designation For SLS009
06 Aug 2024 //
GLOBENEWSWIRE
SELLAS Announces $21.0M Registered Direct Offering At Premium
31 Jul 2024 //
GLOBENEWSWIRE
SELLAS` SLS009 Receives FDA Rare Pediatric Disease Designation For AML
16 Jul 2024 //
GLOBENEWSWIRE
Sellas Receive EMA Orphan Drug Designation For SLS009 For Acute Myeloid Leukemia
08 Jul 2024 //
GLOBENEWSWIRE
SELLAS Gets FDA Rare Pediatric Disease Designation For SLS009 In Pediatric ALL
24 Jun 2024 //
GLOBENEWSWIRE
Sellas Gets IDMC Nod To Continue AML REGAL Phase 3 Trial
18 Jun 2024 //
PHARMABIZ
SELLAS Life Sciences Receives Positive Recommendation For Phase 3 REGAL Trial
17 Jun 2024 //
GLOBENEWSWIRE
SELLAS Announces Enrollment, Positive Phase 2a Data For SLS009 In AML
10 Jun 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports Q1 2024 Results, Corporate Update
14 May 2024 //
GLOBENEWSWIRE
SELLAS: 100% Response In ASXL1 AML With SLS009 In Phase 2
01 May 2024 //
GLOBENEWSWIRE
SELLAS: Positive DMC Rec After REGAL Phase 3 Enrollment Complete
29 Apr 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
SELLAS Announces Positive Data from the Phase 2a Study of SLS009 in r/r AML
26 Mar 2024 //
GLOBENEWSWIRE
SELLAS to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
19 Mar 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Group Announces Closing of $20 M RDO
19 Mar 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering
15 Mar 2024 //
GLOBENEWSWIRE
SELLAS Announces Executive Leadership Reorganization
08 Mar 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data
01 Mar 2024 //
GLOBENEWSWIRE
SELLAS Life to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients
29 Feb 2024 //
GLOBENEWSWIRE
SELLAS Announces Publication of Preclinical Data on its SLS009
06 Feb 2024 //
GLOBENEWSWIRE
SELLAS Life to Present SLS009 Phase 1 from Acute Myeloid Leukemia Patients
25 Jan 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009
09 Jan 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
04 Jan 2024 //
GLOBENEWSWIRE
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
03 Jan 2024 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces Proposed Public Offering
03 Jan 2024 //
GLOBENEWSWIRE
SELLAS Life Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S
27 Dec 2023 //
GLOBENEWSWIRE
SELLAS Receives FDA Orphan Drug Designation for SLS009
21 Dec 2023 //
GLOBENEWSWIRE
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
13 Dec 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces Positive Recommendation in Acute Myeloid Leukemia
04 Dec 2023 //
GLOBENEWSWIRE
SELLAS Reaches Target Enrollment in Phase 3 Trial of Galinpepimut-S
29 Nov 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on CMC
13 Nov 2023 //
GLOBENEWSWIRE
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
SELLAS Presents Immunobiological and Clinical Data from Phase 1/2 Trial of GPS
06 Nov 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces $4 Million Registered Direct Offering
31 Oct 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009
30 Oct 2023 //
GLOBENEWSWIRE
SELLAS Life to Present Final Data from Phase 1/2 Study of Galinpepimut-S
17 Oct 2023 //
GLOBENEWSWIRE
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009
16 Oct 2023 //
GLOBENEWSWIRE
SELLAS Life Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S
12 Oct 2023 //
GLOBENEWSWIRE
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009
11 Oct 2023 //
GLOBENEWSWIRE
SELLAS Receives FDA Orphan Drug Designation for SLS009
10 Oct 2023 //
GLOBENEWSWIRE
SELLAS Announces Positive Data in Lymphoma Cohort from SLS009 Phase 1 Trial
21 Sep 2023 //
GLOBENEWSWIRE
SELLAS Life to Participate in the Cantor Fitzgerald Global Healthcare Conference
18 Sep 2023 //
GLOBENEWSWIRE
SELLAS Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue
22 Aug 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports +ve Data in Completed Ph1 Study of Galinpepimut-S
28 Jun 2023 //
GLOBENEWSWIRE
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009
22 Jun 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces Abstract Accepted for Presentation
15 Jun 2023 //
GLOBENEWSWIRE
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
13 Jun 2023 //
GLOBENEWSWIRE
SELLAS Life to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO
25 May 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in AML
16 May 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
SELLAS Announces +VE Topline Data from GFH009 pH 1 Dose-Escalation Trial in AML
04 May 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Announces Abstract Accepted for Presentation at 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation
20 Apr 2023 //
GLOBENEWSWIRE
SELLAS Life Sciences Independent Data Monitoring Committee
18 Apr 2023 //
GLOBENEWSWIRE
